Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety...

Area of Science:

• Cardiovascular Pharmacology
• Mitochondrial Toxicology
• Drug Safety Assessment

Background:

• Drug-induced cardiotoxicity is a significant cause of drug attrition and cardiovascular disease mortality.
• Proarrhythmic risk assessment is standard in preclinical cardiac safety, but other toxicity mechanisms are overlooked.
• Mitochondrial impairment is a common cardiotoxicity mechanism, linked to over half of FDA black box warnings for cardiovascular adverse events.

Purpose of the Study:

• To review drug-induced mitochondrial toxicities in cardiomyocytes.
• To discuss high-throughput screening strategies for mitochondrial function.
• To propose integrating mitochondrial toxicity assessment into preclinical cardiac safety pharmacology.

Main Methods:

• Review of scientific literature on cardiomyocyte mitochondria and drug toxicity.
• Discussion of high-throughput screening (HTS) methodologies.
• Emphasis on adult human primary cardiomyocytes for morphological and functional evaluation.

Main Results:

• Mitochondrial impairment is a prevalent and under-assessed mechanism of drug-induced cardiotoxicity.
• Adult human primary cardiomyocytes offer advantages for evaluating mitochondrial health.
• Current preclinical safety testing lacks routine integration of mitochondrial toxicity assessment.

Conclusions:

• Mitochondrial dysfunction is a critical aspect of cardiotoxicity that requires dedicated assessment.
• Novel cardiac safety testing platforms should integrate both mitochondrial toxicity and proarrhythmic risk evaluations.
• Standardizing mitochondrial toxicity testing in preclinical stages is essential for improving drug safety and reducing cardiovascular risks.